In a landmark clinical trial, scientists in Japan have demonstrated for the first time that dopaminergic progenitor cells derived from human induced pluripotent stem cells (iPSCs) can be safely transplanted into the brains of Parkinson’s disease (PD) patients—potentially offering a new avenue of regenerative therapy for this progressive neurodegenerative condition.

Published in Nature (Sawamoto et al., 2025), the Phase I/II study at Kyoto University Hospital involved seven patients with moderate-stage Parkinson’s disease, aged between 50 and 69. The researchers transplanted dopamine-producing progenitor cells directly into the putamen—a brain region critical to motor control. These cells were derived from iPSCs generated from a healthy donor’s blood and processed to eliminate any contaminating cell types, such as serotonergic neurons that have previously been linked to post-transplant complications.

Safety and Tolerability Confirmed

Across the two-year monitoring period, no serious adverse events related to the transplant were reported. Mild side effects such as injection site itching and manageable immune reactions were observed in some participants. Crucially, no tumours formed, and imaging confirmed stable integration of the transplanted cells without overgrowth or inflammation.

Patients were given immunosuppressive therapy (tacrolimus) for up to 15 months, after which no immune rejection signs were observed, indicating a favourable safety profile for allogeneic iPSC-derived cell therapy.

Promising Clinical Improvements

Among the six patients evaluated for efficacy, four showed notable improvements in motor function as measured by the MDS-UPDRS Part III during off-medication periods—suggesting real functional gains. One patient improved by 50% on this scale. Importantly, fluorine-18-labeled DOPA PET imaging revealed a 44.7% average increase in dopamine synthesis in the putamen, especially in the high-dose transplant group.

Notably, no cases of graft-induced dyskinesias—a common and troubling side effect in earlier fetal tissue transplants—were observed, likely due to the precise sorting and purification of dopaminergic progenitor cells.

A Measured Step Forward

While the trial lacked a placebo-controlled arm, and the sample size was small, the clinical and imaging outcomes provide compelling preliminary evidence that iPSC-derived dopaminergic cell replacement can safely restore dopamine activity and improve symptoms in PD.

These results open the door to larger, multi-centre, double-blind studies. They also suggest the potential to combine cell therapy with gene-based interventions, medication, or rehabilitation to enhance long-term outcomes. Additionally, the use of autologous iPSCs, which avoid immune rejection altogether, remains an area of intense interest following a successful case in 2020.

Cosmael ThinkLab Commentary

This study marks a critical step in the long journey toward regenerative treatments for neurodegenerative diseases. While still early, it embodies the promise of precision medicine—tailored, cell-based therapies that repair rather than merely compensate for neural damage. The trial also sets a rigorous precedent in safety and quality control for future clinical applications of stem cell technologies.

Source:
Sawamoto, N., Doi, D., Nakanishi, E., et al. (2025). Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature. https://doi.org/10.1038/s41586-025-08700-0